Marinomed Biotech AG

Marinomed Biotech AG announces unanimous approval of the restructuring plan by creditors

Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio

Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share

Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights

Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

Marinomed Biotech AG: Court opens restructuring proceedings without self-administration